RVNC - According to Reuters, Stifel cuts price targets on Allergan, Evolus and Revance, citing a decrease in demand for non-essential medical procedures. Citing a survey of plastic surgeons and dermatologists, Stifel says the number of postponements from March 3 to March 16 has gone up to 19% from 58% [sic].... Physicians now expect the impact of the outbreak will be worse than the last economic downturn of 2008, with neurotoxins as the most resilient procedures.
RVNC target from 40 to 35.
Market Data 
Markets 
AI
